Canaccord Genuity Maintains a 'Hold' on Vertex (VRTX); Cutting Incivek Estimates
Tweet Send to a FriendGet Alerts VRTX Hot Sheet
Price: $78.40 -0.1%
Rating Summary:
17 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
17 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade VRTX Now!
Canaccord Genuity maintains a 'Hold' on Vertex (NASDAQ: VRTX) price target of $34.00.
Analyst, George Farmer, said, "Recent stock momentum in the face of Incivek pressures may, in our view, be attributed to perception of asset diversification value from Kalydeco approval and removal of an Incivek sales guidance overhang. Beyond Kalydeco, we do not believe VRTX’s CF program will drive meaningful upside to shares unless positive VX-809 Phase II data emerges, possibly mid-year. Lackluster prior Phase II data significantly handicaps this outcome, in our view."
"Maintaining our thesis of 2015 drop-off in Incivek sales upon emergence of the nuc prodrug class into the HCV market, we now further subdue our 2012, 2013, and 2014 estimates to $1.65B, $1.74B, and $1.78B from $2.46B, $2.62B, and $2.89B, reflecting nominal growth from management’s 2012 assumptions."
For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.
Shares of Vertex closed at $38.38 yesterday, with a 52 week range of $26.50-$58.87.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, George Farmer, said, "Recent stock momentum in the face of Incivek pressures may, in our view, be attributed to perception of asset diversification value from Kalydeco approval and removal of an Incivek sales guidance overhang. Beyond Kalydeco, we do not believe VRTX’s CF program will drive meaningful upside to shares unless positive VX-809 Phase II data emerges, possibly mid-year. Lackluster prior Phase II data significantly handicaps this outcome, in our view."
"Maintaining our thesis of 2015 drop-off in Incivek sales upon emergence of the nuc prodrug class into the HCV market, we now further subdue our 2012, 2013, and 2014 estimates to $1.65B, $1.74B, and $1.78B from $2.46B, $2.62B, and $2.89B, reflecting nominal growth from management’s 2012 assumptions."
For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.
Shares of Vertex closed at $38.38 yesterday, with a 52 week range of $26.50-$58.87.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: A.G. Lafley Gives Procter & Gamble (PG) Investors 'New Hope', UBS Upgrades to Buy
- Jefferies Bumps Zumiez (ZUMZ) Numbers Up, But Remains on Sidelines
- Imperial Capital Boosts Price Target on Dick's (DKS); 'Best-of-Breed'
Create E-mail Alert Related Categories
Analyst CommentsComments
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
lackluster phase II trial data
gary on Feb 3, 2012 04:45 PMMark as Spam | Reply to this comment
I'm just wondering were you got your information on lackluster phase two data in regards to congoing clinical trials concerning a combination of 770 and 809 in those with the 508 mutation. I'm not saying your wrong, but few reports i have read indicate promising results.